For many years there have been two schools of thought concerning the aetiology of Schizophrenia. Some psychiatrists have been impressed by the disturbed family relationships and early upbringing that is commonly seen in cases of schizophrenia and have felt that the condition is largely psychogenic: that is that anyone subjected to these malign influences would develop the disease. Other psychiatrists have felt that schizophrenia results from a genetically determined metabolic disorder and that the disturbed behaviour results from a brain with specific faults in its biochemical mechanism.
Som e psychiatrists have been im pressed by the disturbed fam ily relationships and early upbringing that is com m only seen in cases o f schizophrenia and have felt that the condition is largely p sy ch o g en ic: that is that anyone subjected to these m align influences would develop the disease. O ther psychiatrists have felt that schizophrenia results from a genetically determ ined m etabolic disorder and that the disturbed behaviour results from a brain w ith specific faults in its biochem ical m echanism .
T w o recent studies o f w hat happens to the children o f schizophrenic m others who have been removed from their m others shortly after birth and reared in foster hom es have provided powerful, and I believe conclusive, evidence in favour o f the latter view. T h is w ork was car ried out by H eston in O regon and by R osen thal and K ety in D enm ark. T h e results show ed that these children in foster fam ilies nevertheless developed schizophrenia at the same rate (about 1 2 % -as com pared w ith the norm al expectancy of 0.8% ) as do the children of one schizophrenic parent reared b y their biological m other. A control group o f adopted children o f norm al m others reared in sim ilar foster hom es showed no increased incidence. T h en the foster fam ilies in which these child ren actually developed schizophrenia were com pared with those in w hich the children rem ained norm al, and no difference could be detected between them . B oth lots appeared to be ordinary fam ilies. T h u s w hat counts for the developm ent of schizophrenia appears to be the genes and not the early fam ily environ m ent. M oreover m any of the children o f a schizophrenic m other, who did not develop actual schizophrenia, were abnorm al having various severe form s o f psychopathic person ality. T h is would therefore account for the fact that m any of the relatives of schizophrenics have abnorm al personalities and for the fact that m any schizophrenics com e from peculiar fam ilies.
H ow ever environm ental influence also play a role in the genetic expression, which is o f course true for any gentically determ ined condition, such as diabetes, and even for in fections, such as tuberculosis.
In identical twins, if one twin has schizophrenia, th e other is affected in only about 4 0 % of cases. B u t the affected twin is alm ost always the sm aller and weaker w ith signs o f relatively defective intra uterine nourishm ent.
T h e prognosis o f the illness also depends, of course, on environm ental and psychogenic factors. B u t the present evidence is th at m ost schizophrenics are fated from birth to develop the condition.
If then schizophrenia is genetically determ in ed, presum ably the faulty gene or genes arc expressed by som e faulty enzyme(s) whose malfunction leads to disorders in the brain mechanisms underlying thinking, emotional responses and the generation of belief and behaviour. In search for clues as to what the system concerned might be people have studied the mode of action of drugs that can induce a schizophrenia-like reaction (i.e. hallu cinogens such as LSD ) and those that are of therapeutic value in the illness (i.e. the phenothiazines and butyrophenones). T o take these in turn. T h e hallucinogens produce many different effects in different people, but some times they include a 'bad trip' which is an acute psychosis with many points of similarity with an acute schizophrenic breakdown. T h e formulae for some well-known hallucinogens is shown in figure 1. It will be noted that many are close chemical relations to the neurotransmitters serotonin and dopamine, the simplest relation being O-methylation, Nmethylation or both.
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This relation ship led Osmond, HarleyMason and Smythies to suggest in 1952 that schizophrenia might be associated with some disorder of catecholamine metabolism so that mescaline-like compounds were produced in the brain such as D M P E ( fig. 2 ). Although this compound has been shown to be a normal constituent of urine (possibly of dietary origin) there is evidence that its levels are not raised in schizophrenics. However it is possible that schizophrenics may be abnormally sensitive to it, particularly since it has been reported that schizophrenics are abnormally sensitive to the psychotoxic properties of its close chemical relative 2,3,4-trimethoxy phenylethylamine ( fig.  3 ). T h is possibility can easily be tested by experiment.
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, 4 d i m e t h o x y p h e n y l e t h y l a m i n e
Another approach to this problem derives from the discovery made by Pollin et al in 19 6 1 that some chronic schizophrenics react to l-methionin with an acute psychosis. Th is has now been confirmed by four groups of workers.
In some cases the psychosis shows features of a toxic psychosis and in others of an acute schizophreniform psychosis. About 50% of schizophrenics react and the rest show no re action at all. It is not possible to predict on clinical grounds which patients will react and which will not. T h e dose of 1-methionine required is quite small (10-20 C/day) and this dose produces no reaction in normal people. Recently an unconfirmed report from Poland claims that methionine increases the excretion of dimethyltryptamine in schizophrenics but only in those that react to methionine. Thus the basis of the methionine effect may be to increase transmethylation processes in the brain since methionine is the origin of the methyl groups in all transmethylation reaction in the body. Other unconfirmed reports in this field are that schizophrenics do not react with a toxic psychosis as normal people do to the methionine antimetabolite M SO (methionine sulphoxamine) at a dosage of 300 mg/day. Also that schizophrenics methionine meta bolism is different from normals. M ethionine with a C 14 label on the labile methyl group was given to schizophrenics and normal controls and the rate of excretion of C 14O2 was measured.
This was much slower in the schizophrenics indicating an overactive transmethylating pool.
However we cannot assume that methionine induces its effects by some action on the trans methylation system, for it has other potent biological actions. For example 20 G 1-methionine a day will cause an upset in the uptake of all the other amino acids and it will also affect secondarily tryptophan metabolism.
T h e problems of how it does produce its effects in schizophrenics can only be settled by further experiment.
W e can now ask how do hallucinogens produce their effects on brain function for that may give us a clue as to the site of the disorder in schizophrenia. T h eir most marked property is to block central serotonin mechanisms.
This has been determined both by micro injection techniques onto the surface of individual neurones and by the following technique. M ost of the serotonin containing neurones in the brain locate their cell bodies in the raphe nuclei of the brain stem. From here the axons are distributed all over the rest of the brain. Th is system seems to control slow-wave sleep amongst other things. If re cordings are made from this nucleus and d-L S D injected intravenously an abrupt cessation of firing results.
In addition -to these drugs that mimic schizophrenia, we now know of several classes that alleviate it and are used in its clinical treatment. This includes the phenothiazines (such as chlorpromazine), the butyrophenones (such as haloperidol) and certain diphenylbutylpiperazines (such as pimozide). These have a very wide range of biological effects but pro minent amongst them is the inhibition of catecholamines. Pimozide, in particular, has potent anti-dopamine actions. This suggests that schizophrenia may be associated with excess activity in the adrenergic and particular ly the dopamine system, or it may not be the absolute level of activity in these systems that may be as important as their relative level or balance. If the serotonin system is blocked there may be a relating imbalance of the ad renergic or dopamine systems. T h e thera peutic action of the anti-psychotic drugs may thus depend on their ability to reduce this (relative) excess activity in the adrenergic system so that it comes back into balance with the serotonin system again.
Another way to treat schizophrenia would be to develop drugs that would so act on the serotonin receptor in brain that the binding of hallucinogens (such as dimethyltryptamine) would be blocked but serotonin itself could still bind. W e are currently working on de veloping such a drug based on the 'top half' of L S D . Figure 3 shows a compound we have called T H P C (N-methyl-1,2,4,6 tetrahydropyridine carboxamide). This is a close approx imation to the top half of d-LSD. If it were to bind in the same locus as where d-LSD itself acts, clearly d-LSD itself could no longer bind, but mescaline itself, which approximates in shapes to the A + B rings of d-LSD, could. Therefore one would predict that T H P C would block the effects of d-LSD but potentiate the effects of mescaline. This prediction was test ed using a conditioned avoidance test in rats that enables us to measure the 'psychotomi metic' activity of a drug and was confirmed. T H P C was also shown to block the effects of dimethyltryptamine. Clearly then T H P C may be useful in the treatment of an L S D psychosis and if schizophrenia is caused by a compound like dimethyltryptamine, T H P C might prove
THPC of therapeutic benefit, whereas if the com pound responsible was more like mescaline, T H P C should exacerbate the illness. Thus T H P C can be used as a molecular probe to try and determine the nature of the psychotoxin of schizophrenia. Even if it had no effect, this would provide useful evidence -i.e. that no compounds similar to dimethyltryptamine or to mescaline were involved. N ow although the bulk of recent research in schizophrenia has been based on the trans m ethylation hypothesis, other lines o f study have produced som e prom ising results. It has been know n for years that chronic schizo phrenics have a peculiar odour. R ecen tly a claim has been m ade th at the substance re sponsible has been identified ( fig. 4 ). T h is was found in the sweat o f 1 0 / 1 0 schizophrenics and in no norm al controls. It did not appear to be th e product o f som e bacterial flora pecu liar to chronic hospital wards. T h e com pound certainly has a m ost characteristic and pene trating odour. H ow ever it belongs to a chem ical fam ily -a branched chain unsatur ated fatty acid -never before connected with brain function. In fact the only com pounds I know o f related to it that have a know n b io logical activity are the bee ovarian horm ones, Q ueen Substance and R oyal Jelly , but this m ay be no m ore than a coincidence. A t any event if this report is confirm ed, vigorous efforts should be m ade to trace its m etabolic origin.
A very large num ber o f other investigations have been carried out in schizophrenics but none has achieved any very notable results. Som etim es positive results have been claim ed b u t subsequent work has shown these to be artefactual or due to m alnutrition, non-specific stress and other sim ilar factors. T h is very lack of success has had negative results.
T h e answer to the problem o f schizophrenia can only com e from an intensive research effort directed towards discovering its biochem ical basis. U nfortunately the skilled biochem ists and other biological scientists needed to w ork o n such a program m e are not attracted to w hat has proven over the last 50 years to be so u n rewarding a field. T h e bulk of biochem ical research in psychiatry is currently focussed on the biochem ical basis o f depression, in the form of very extensive work on the biochem istry of cerebral am ines -their m etabolism , uptake, storage and release m echanism s -w h ich has already paid handsom e dividends including N ob el Prizes to tw o o f the m ain workers in this field. In contrast the field o f schizophrenia research is alm ost totally neglected both in E u ro pe and N orth A m erica w hich is strange when one considers the enorm ous econom ic cost to the com m unity and the cost in hum an suffering and blighted lives that schizophrenia brings about. It is not com m only realized that about one in 12 0 people w ill develop the illness at som e point during their lives and that slightly less than one-quarter o f the hospital beds in the country are occupied b y schizophrenics.
H ow ever, now that we possess at last one valid fact about the physiology o f schizophrenia -the m ethionine effect -the im m ediate way ahead is clear. T h e biochem ical basis o f the effect m ust be determ ined. Is it due to altered transm ethylation reactions, to changed patterns of am inoacid uptake, to disturbances in trypto phan m etabolism or to som e other factor? T h e answer to this question m ay w ell lead to other research program m es that in turn may further our understanding of the biochem ical basis o f one o f the still outstanding problem s o f m edicine.
